Yves Rosenberg
Overview
Explore the profile of Yves Rosenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
4203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ingraham B, Farkouh M, Lennon R, So D, Goodman S, Geller N, et al.
JACC Cardiovasc Interv
. 2023 Apr;
16(7):816-825.
PMID: 37045502
Background: Genetic-guided P2Y inhibitor selection has been proposed to reduce ischemic events by identifying CYP2C19 loss-of-function (LOF) carriers at increased risk with clopidogrel treatment after percutaneous coronary intervention (PCI). A...
12.
Self W, Shotwell M, Gibbs K, de Wit M, Files D, Harkins M, et al.
JAMA
. 2023 Apr;
329(14):1170-1182.
PMID: 37039791
Importance: Preclinical models suggest dysregulation of the renin-angiotensin system (RAS) caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II compared with angiotensin (1-7) and may be an...
13.
Hochman J, Anthopolos R, Reynolds H, Bangalore S, Xu Y, OBrien S, et al.
Circulation
. 2022 Nov;
147(1):8-19.
PMID: 36335918
Background: The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) compared an initial invasive versus an initial conservative management strategy for patients with chronic coronary...
14.
Casey J, Beskow L, Brown J, Brown S, Gayat E, Gong M, et al.
Lancet Respir Med
. 2022 Jun;
10(7):700-714.
PMID: 35709825
Unique challenges arise when conducting trials to evaluate therapies already in common clinical use, including difficulty enrolling patients owing to widespread open-label use of trial therapies and the need for...
15.
Avram R, So D, Iturriaga E, Byrne J, Lennon R, Murthy V, et al.
JMIR Form Res
. 2022 Jun;
6(6):e34080.
PMID: 35699977
Background: The Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI) Digital Study is a novel proof-of-concept study that evaluated the feasibility of...
16.
Lamas G, Anstrom K, Navas-Acien A, Boineau R, Kim H, Rosenberg Y, et al.
Am Heart J
. 2022 May;
252:1-11.
PMID: 35598636
Background: Intravenous edetate disodium-based infusions reduced cardiovascular events in a prior clinical trial. The Trial to Assess Chelation Therapy 2 (TACT2) will replicate the initial study design. Methods: TACT2 is...
17.
Moskowitz A, Shotwell M, Gibbs K, Harkins M, Rosenberg Y, Troendle J, et al.
Chest
. 2022 May;
162(4):804-814.
PMID: 35504307
Mortality historically has been the primary outcome of choice for acute and critical care clinical trials. However, undue reliance on mortality can limit the scope of trials that can be...
18.
Mark D, Spertus J, Bigelow R, Anderson S, Daniels M, Anstrom K, et al.
Circulation
. 2022 Mar;
145(17):1294-1307.
PMID: 35259918
Background: ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) compared an initial invasive treatment strategy (INV) with an initial conservative strategy in 5179 participants with chronic...
19.
Hu K, Tardif J, Huber M, Daly M, Langford A, Kirby R, et al.
Clin Transl Sci
. 2021 Dec;
15(4):831-837.
PMID: 34953032
Randomized controlled trials (RCTs) remain the gold standard to evaluate clinical interventions, producing the highest level of evidence while minimizing potential bias. Inadequate recruitment is a commonly encountered problem that...
20.
Arrigo M, Price S, Baran D, Poss J, Aissaoui N, Bayes-Genis A, et al.
Lancet Respir Med
. 2021 Jul;
9(10):1192-1202.
PMID: 34245691
Acute myocardial infarction complicated by cardiogenic shock (AMICS) is a critical syndrome with a high risk of morbidity and mortality. Current management consists of coronary revascularisation, vasoactive drugs, and circulatory...